Hangzhou Kang Ming Information Technology Co., Ltd, trading under the banner of “ClouDr” on the Hong Kong stock exchange (HKG: 9955), has announced that it has secured marketing approval from the National Medical Products Administration (NMPA) for its innovative digital medicine product, ClouDT-01, designed for the treatment of diabetes.
Leveraging ClouDr’s advanced AI models, extensive diabetes service management database, and profound clinical experience in diabetes care, ClouDT-01 employs cutting-edge link technology to conduct a thorough analysis of the entire diabetes care continuum. It pinpoints the unmet needs often overlooked by conventional treatment methods. The product is designed to enhance clinical outcomes for diabetic patients by offering dynamic monitoring and real-time management features.- Flcube.com
